Connect with us

Headlines of The Day

Metropolis Q4FY24: PAT jumps 8% to Rs. 36.1 crore; revenue up 11%

Metropolis Healthcare Ltd has announced Q4FY24 results. PAT increased 8 percent to Rs. 36.1 crore in Q4FY24 against Rs 33.5 crore in Q4FY23.

Revenue from operations increased 11 % YoY to Rs 313 crore in Q4FY24 against Rs 282 crore in Q4FY23.

Core business revenue increased 15% to Rs 308 crore in Q4FY24 against Rs 267 crore in Q4FY23.

For Q4 FY24, EBITDA grew 14 % to Rs 82.4 crore against Rs 72.5 in Q4 FY23.

Core business patient volume stood at 2.98 million for Q4FY24 and 11.59 million for FY24 with a growth of 7% & 9% respectively on a YoY basis

TruHealth Wellness & Specialized segment revenues grew by 22% & 17% respectively for Q4FY24 on YoY basis

Reported EBITDA stood at 25.5% for Q4FY24. EBITDA before CSR & ESOP stood at 26.4%.

The contribution of premium wellness stood at 15% in Q4FY24.

“We have consistently surpassed industry volume growth for the past eight quarters and remain optimistic about continuing this trend. Despite significant network expansion over the last two years, we achieved EBITDA margins of 25.5% in Q4 FY24. Looking ahead, we expect additional revenue from both existing and new networks, coupled with improved operational efficiency, to sustain our current margin levels in FY25 and further enhance our margin profile beyond FY25,” said Ameera Shah, Managing Director, Metropolis Healthcare Ltd.

“Over the past many years, we have been focusing on professionalizing the company and have been adding talent to our senior management team. With Surendran & the team of CXOs, in place and delivering results, I am more confident of achieving greater heights. We believe this is an appropriate time for me to hand over the baton to Surendran & team to execute our strategies, while I will move to the position of Executive Chairperson & Whole Time Director with a steady focus on driving the strategy, strengthening governance, strategizing capital allocation, acquiring talent and foster the culture at Metropolis. As we progress with our Metropolis 3.0 strategy, along with organic growth via existing network and expansion. M&A will be pivotal in elevating our position. Our goal is to enhance our technical testing capabilities and enter new markets, bolstering our strengths and ensuring sustainable growth.”
MB Bureau

Copyright © 2024 Medical Buyer

error: Content is protected !!